Resource Summary Report

Generated by dkNET on Sep 3, 2026

SU-DHL-8

RRID:CVCL_2207
Type: Cell Line

Proper Citation

RRID:CVCL_2207

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2207

Proper Citation: RRID:CVCL_2207

Description: Cell line SU-DHL-8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: PMID:83902, PMID:177185, PMID:214220, PMID:371794, PMID:3881165, PMID:8547074, PMID:19278952, PMID:20628145, PMID:22460905, PMID:25355872, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30285677, PMID:30629668, PMID:30894373, PMID:30971826, PMID:31068700, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-8

Synonyms: SUDHL8, SUDHL-8, SuDHL 8, Stanford University-Diffuse Histiocytic Lymphoma-8, DHL-8, DHL8

Cross References: CLO:CLO_0037064, EFO:EFO_0006493, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2961, BioGRID_ORCS_Cell_line:1026, BioSample:SAMN03471060, BioSample:SAMN10988104, cancercelllines:CVCL_2207,

Cell_Model_Passport:SIDM00423, ChEMBL-Cells:CHEMBL4523531, ChEMBL-Targets:CHEMBL4523562, CLS:305877, Cosmic:1067442, Cosmic:1079256, Cosmic:1295511, Cosmic:1517639, Cosmic:1541913, Cosmic:1636689, Cosmic:2276342, Cosmic:2361381, Cosmic:2437316, Cosmic-CLP:1331038, DepMap:ACH-000656, DSMZ:ACC-573, DSMZCellDive:ACC-573, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1331038, GEO:GSM380149, GEO:GSM552467, GEO:GSM887656, GEO:GSM888748, GEO:GSM1035316, GEO:GSM1374909, GEO:GSM1670488, IARC_TP53:28301, LiGeA:CCLE_179, LINCS_LDP:LCL-1139, PharmacoDB:SUDHL8_1505_2019, PRIDE:PXD030304, Progenetix:CVCL_2207, PubChem_Cell_line:CVCL_2207, Wikidata:Q54970731

ID: CVCL_2207

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260904T015759+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-8.

No alerts have been found for SU-DHL-8.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Shi X, et al. (2025) NFS1, together with FXN, protects cells from ferroptosis and DNA damage in diffuse large B-cell lymphoma. Redox biology, 87, 103878.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. Molecular cell, 85(13), 2597.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Dietz A, et al. (2020) Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International journal of cancer, 147(5), 1485.

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell chemical biology, 27(5), 538.

Yamagishi M, et al. (2019) Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. Cell reports, 29(8), 2321.